Selection criteria for large core trials: rationale for the ANGEL-ASPECT study design

Zeguang Ren, Xiaochuan Huo, Gaoting Ma, Xu Tong, Jay Kumar, Elliot Pressman, Wenhuo Chen, Guangxiong Yuan, Alvin Yi-Chou Wang, Ming Wei, Jiangang Zhang, Guangxian Nan, Qiyi Zhu, Yajie Liu, Liyong Zhang, Weigen Song, Zhiming Zhou, Guoqing Wang, Tianxiao Li, Jun Luo, En Wang, Wentong Ling, Dongsheng Ju, Cunfeng Song, Shudong Liu, Liqiang Gui, Tong Li, Yan Liu, Junfeng Zhao, Zaiyu Guo, Hongbo Zheng, Yaxuan Sun, Na Xu, Yong Jun Wang, Zhongrong MiaoJournal of NeuroInterventional Surgery 2021 · DOI

Introduction

Recent clinical discourse regarding endovascular thrombectomy (EVT) for large core acute ischemic stroke (AIS) has highlighted significant variability in trial eligibility criteria. While EVT is the established standard for small-core strokes, its efficacy in patients with extensive baseline damage—"large core" strokes—remains a critical frontier in neurointerventional surgery. The ANGEL-ASPECT trial (NCT 04551664), currently the only large core trial focused on the Chinese population, offers a unique methodological perspective that addresses several ethical and diagnostic challenges identified in contemporary debates.

The Challenge of Patient Selection

The primary hurdle in large core trials is the accurate definition and measurement of the ischemic core. Two dominant methods currently exist:

  1. Alberta Stroke Program Early CT Score (ASPECTS): A visual 10-point scoring system for non-contrast CT. While rapid, it suffers from high inter-rater variability.
  2. CT Perfusion (CTP) or Diffusion-Weighted MRI (DWI-MRI): Automated software that calculates tissue volume. While objective, these can overestimate damage in the hyperacute phase, potentially excluding patients who might still benefit from reperfusion.

The central tension in trial design is ensuring that patients who are already known to benefit from EVT are not randomized into "no-treatment" control groups, while simultaneously identifying those with cores so large that treatment would be futile or harmful.

The ANGEL-ASPECT Methodology

The ANGEL-ASPECT trial employs a tiered, hybrid imaging strategy designed to minimize subjectivity and maximize the identification of "true" large cores. Unlike the SELECT-2 trial, which relies heavily on CTP/DWI-MRI, ANGEL-ASPECT uses a multi-step approach:

  • Tier 1 (Primary Inclusion): Patients presenting within 24 hours with an ASPECTS score of 3–5 are enrolled based on visual CT assessment alone.
  • Tier 2 (Secondary Validation): Advanced imaging (CTP or MRI) is used as a "tie-breaker" in specific scenarios, such as when the ASPECTS score is >5 but the patient is in the late window (>6 hours), or if the score is <3.
  • Volume Thresholds: The trial defines a large core as a volume between 70–100 cc.

Comparative Insights and Ethical Considerations

A key differentiator of ANGEL-ASPECT is its handling of the "gray zone"—patients with core volumes between 50–70 cc. Existing evidence suggests this group likely benefits from EVT. By excluding them from the trial, the researchers avoid the ethical dilemma of randomizing patients to a potentially inferior "no-treatment" arm.

Furthermore, the trial expands the treatment window to 24 hours, testing the durability of EVT's benefit in large cores well beyond the traditional 6-hour limit. In comparison to other global trials such as TENSION, LASTE, and SELECT-2, ANGEL-ASPECT is unique in its specific volume range and its focus on the Asian population, where intracranial atherosclerotic disease is more prevalent.

Preliminary Observations and Future Directions

Current enrollment data indicates that CTP-based inclusion accounts for only approximately 10% of the total study population. This suggests that traditional CT remains a robust tool for identifying the majority of large core cases, with advanced imaging serving as a vital safety valve for ambiguous presentations.

The ultimate goal of the ANGEL-ASPECT trial is to determine if EVT provides a functional benefit regardless of the presence of a "penumbra" (salvageable tissue) on advanced imaging. If successful, this could streamline stroke workflows by allowing clinicians to bypass time-consuming perfusion scans and move directly to intervention, adhering to the principle that "time is brain."

Conclusion

The ANGEL-ASPECT trial provides a refined framework for large core stroke research. By balancing subjective visual scores with objective volumetric data and respecting established benefit thresholds, the study design aims to provide definitive evidence for EVT in a challenging patient population while maintaining the highest ethical standards in clinical trial methodology.

Summary updated

Abstract

Two recently published JNIS commentaries 1 2 on eligibility criteria for the clinical trials on patients with large core, acute ischemic stroke (AIS) with large vessel occlusion have caused some debate. Five trials were included. 1 Our ongoing trial, ANGEL-ASPECT (NCT 04551664), which represents the only large core trial currently ongoing in the Chinese population, was not included in the discussion. One issue of the debate is the addition of CT perfusion (CTP)/ diffusion-weighted image of magnetic resonance imaging (DWI-MRI) to the inclusion criteria, which only the SELECT-2 trial chose to adopt. This raised concern about whether patients already known to benefit from endovascular thrombectomy (EVT) are being randomized to EVT treatment or no treatment. Like the SELECT-2 trial, our ANGEL-ASPECT trial also added CTP/ DWI-MRI to our inclusion criteria, but in a manner different from SELECT-2. Here we review the merits of ANGEL-ASPECT's design and suggest that it be included in the discussion of patient selection criteria in large core trials.
BibTeX
@article{ren2021selection,
  author = {Zeguang Ren and Xiaochuan Huo and Gaoting Ma and Xu Tong and Jay Kumar and Elliot Pressman and Wenhuo Chen and Guangxiong Yuan and Alvin Yi-Chou Wang and Ming Wei and Jiangang Zhang and Guangxian Nan and Qiyi Zhu and Yajie Liu and Liyong Zhang and Weigen Song and Zhiming Zhou and Guoqing Wang and Tianxiao Li and Jun Luo and En Wang and Wentong Ling and Dongsheng Ju and Cunfeng Song and Shudong Liu and Liqiang Gui and Tong Li and Yan Liu and Junfeng Zhao and Zaiyu Guo and Hongbo Zheng and Yaxuan Sun and Na Xu and Yong Jun Wang and Zhongrong Miao},
  title = {{Selection criteria for large core trials: rationale for the ANGEL-ASPECT study design}},
  journal = {Journal of NeuroInterventional Surgery},
  year = {2021},
  doi = {10.1136/neurintsurg-2021-017798},
}
Figure